

Simcere flu facility gets SFDA's GMP nod

25 March 2013 | Regulatory | By BioSpectrum Bureau



Singapore: China SFDA has approved Simcere Pharmaceutical's GMP certification of the influenza vaccine production facility at Jiangsu Simcere Vaxtec Bio-Pharmaceutical, a subsidiary in which the company holds a 52.50 percent equity interest.

Separately, the company also announced the resignation of Mr Hong Zhao, an executive vice president of the company. Mr Zhao resigned for personal reasons. His resignation has been accepted by the company and will be effective April 1, 2013.